- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07931547
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both (AMBITION 2)
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Placebo in Participants With Type 2 Diabetes and Chronic Kidney Disease Inadequately Controlled on Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
The study is testing zenagamtide in participants with type 2 diabetes and chronic kidney disease. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. Participants will either get zenagamtide or placebo. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
- Имя: Novo Nordisk
- Номер телефона: (+1) 866-867-7178
- Электронная почта: clinicaltrials@novonordisk.com
Места учебы
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90430-001
- Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90035-903
- Hospital de Clínicas de Porto Alegre_Porto Alegre
-
-
São Paulo
-
Campinas, São Paulo, Бразилия, 13060-080
- Instituto de Pesquisa Clínica de Campinas
-
São Paulo, São Paulo, Бразилия, 01228-000
- CPQuali Pesquisa Clínica Ltda
-
-
-
-
-
Bad Mergentheim, Германия, 97980
- Diabetespraxis Mergentheim
-
Berlin, Германия, 13597
- Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR
-
Ludwigshafen, Германия, 67059
- Die Praxis am Ludwigsplatz
-
Mainz, Германия, 55116
- Gesundheitscentrum Mainz (Regner / Schmitt)
-
Münster, Германия, 48153
- MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin
-
Pirna, Германия, 01796
- Hausärztliche und Diabetologische Praxis Pirna
-
Pohlheim, Германия, 35415
- ceda - Centrum für Diabetologie und Allgemeinmedizin Pohlheim
-
-
-
-
-
New Delhi, Индия, 110029
- All India Institute of Medical Sciences (AIIMS)
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, Индия, 522001
- Endolife Specialty Hospitals
-
-
Chhattisgarh
-
Raipur, Chhattisgarh, Индия, 492099
- All India Institute of Medical Sciences (AIIMS), Raipur
-
-
Gujarat
-
Vadodara, Gujarat, Индия, 390001
- SSG Hospital, Baroda
-
-
Karnataka
-
Bangalore, Karnataka, Индия, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kozhikode, Kerala, Индия, 673008
- Government Medical College, Kozhikode
-
-
Maharashtra
-
Kohlapur, Maharashtra, Индия, 416001
- Shree Mahalaxmi DIATONE Institute
-
Kolhāpur, Maharashtra, Индия, 416008
- Excel Endocrine Centre
-
Pune, Maharashtra, Индия, 411002
- Shree Samarth Hospital
-
-
Punjab
-
Ludhiana, Punjab, Индия, 141001
- Dayanand Medical College & Hospital
-
-
Rajasthan
-
Jaipur, Rajasthan, Индия, 302004
- SMS Medical College & Hospital
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Индия, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Индия, 500082
- NIZAM'S Institute of Medical Sciences
-
-
-
-
Anhui
-
Hefei, Anhui, Китай, 230012
- The Second People's Hospital of Hefei-Endocrinology
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Китай, 404199
- Chongqing University Three Gorges Hospital-Endocrinology
-
-
Guangdong
-
Huizhou, Guangdong, Китай, 516001
- Huizhou Central People's Hospital-Endocrinology
-
Shenzhen, Guangdong, Китай, 518035
- The Second People's Hospital of Shenzhen-Endocrinology
-
-
Hebei
-
Hengshui, Hebei, Китай, 053000
- Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology
-
Shijiazhuang, Hebei, Китай, 050000
- The Second Hospital of Hebei Medical University-Endocrinology
-
-
Henan
-
Kaifeng, Henan, Китай, 475000
- Huaihe Hospital of Henan University-Endocrinology
-
Luoyang, Henan, Китай, 471003
- The First Affiliated Hospital of Henan University of Science and Technology-Endocrinology
-
Luoyang, Henan, Китай, 471002
- Luoyang First People's Hospital-Endocrinology
-
Nanyang, Henan, Китай, 473058
- The First Affiliated Hospital of Nanyang Medical College-Endocrinology
-
-
Hunan
-
Changde, Hunan, Китай, 415003
- The First People's Hospital of Changde City-Endocrinology
-
-
Jiangsu
-
Changzhou, Jiangsu, Китай, 213004
- The First People's Hospital of Changzhou-Endocrinology
-
Nanjing, Jiangsu, Китай, 210011
- The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
-
Zhenjiang, Jiangsu, Китай, 212001
- The Affiliated Hospital of Jiangsu University-Endocrinology
-
-
Jilin
-
Jilin City, Jilin, Китай, 130041
- The Second Norman Bethune Hospital of Jilin University-Endocrinology
-
-
Shandong
-
Jinan, Shandong, Китай, 250013
- Jinan Central Hospital-General Medicine
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 201200
- Shanghai Pudong New Area People's Hospital-Endocrinology
-
-
Sichuan
-
Chengdu, Sichuan, Китай, 610071
- Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Affiliated Hospital of UESTC-Endocrinology
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Китай, 300070
- Tianjin Medical University Chu Hsien-I Memorial Hospital-Endocrinology
-
-
Zhejiang
-
Huzhou, Zhejiang, Китай, 313000
- Huzhou Central Hospital-Endocrinology
-
-
-
-
-
Gdansk, Польша, 80-214
- Uniwersyteckie Centrum Kliniczne
-
Gmina Świecie, Польша, 86-100
- Nowy Szpital Sp. z o.o.
-
Lublin, Польша, 20-601
- Zanamed Medical Clinic Sp. z o.o.
-
Olsztyn, Польша, 10-117
- Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.
-
Olsztyn, Польша, 10-561
- Wojewodzki Szpital Specjalistyczny w Olsztynie
-
Oświęcim, Польша, 32-600
- Formed 2 Sp. z o.o.
-
Warsaw, Польша, 02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
Zabrze, Польша, 41-800
- Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko
-
-
Silesian Voivodeship
-
Chorzów, Silesian Voivodeship, Польша, 41-500
- M2M Med. Badania Sp. z o.o.
-
-
-
-
California
-
La Jolla, California, Соединенные Штаты, 92037
- Scripps Whittier Diabetes Inst
-
Lancaster, California, Соединенные Штаты, 93534
- First Valley Medical Group
-
Lincoln, California, Соединенные Штаты, 95648
- Headlands Research CTR Lincoln
-
San Dimas, California, Соединенные Штаты, 91773
- North America Research Institute
-
-
Florida
-
Fleming Island, Florida, Соединенные Штаты, 32003
- Northeast Research Institute
-
Hollywood, Florida, Соединенные Штаты, 33024
- Encore Medical Research LLC
-
Miami, Florida, Соединенные Штаты, 33155
- My Preferred Research
-
Mt. Dora, Florida, Соединенные Штаты, 32757
- Adult Medicine of Lake County, Inc
-
Ocoee, Florida, Соединенные Штаты, 34761
- West Orange Endocrinology
-
Orlando, Florida, Соединенные Штаты, 32825
- Florida Inst For Clin Res LLC
-
Tamarac, Florida, Соединенные Штаты, 33321
- Care Access
-
Weston, Florida, Соединенные Штаты, 33331
- Encore Medical Research of Weston
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты, 89148
- Palm Research Center Inc-Vegas
-
-
New York
-
Brooklyn, New York, Соединенные Штаты, 11220
- DM Clinical
-
-
North Carolina
-
Chapel Hill, North Carolina, Соединенные Штаты, 27514
- University of North Carolina Chapel Hill
-
Morehead City, North Carolina, Соединенные Штаты, 28557
- Carteret Medical Group
-
-
South Carolina
-
Spartanburg, South Carolina, Соединенные Штаты, 29303
- Spartanburg Medical Research
-
-
Tennessee
-
Bristol, Tennessee, Соединенные Штаты, 37620-7352
- Holston Medical Group Pc
-
Chattanooga, Tennessee, Соединенные Штаты, 37404
- Southeast Renal Research Institute
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Clinical Research Associates
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77081
- Southwest Clinical Trials
-
Houston, Texas, Соединенные Штаты, 77024
- Victorium Clinical Research
-
Houston, Texas, Соединенные Штаты, 77054
- Prolato Clinical Research Cntr
-
Katy, Texas, Соединенные Штаты, 77450
- Medical Colleagues-Texas LLP
-
San Antonio, Texas, Соединенные Штаты, 78233
- Northeast Clinical Research of San Antonio
-
Shavano Park, Texas, Соединенные Штаты, 78231
- Consano Clinical Research, LLC
-
-
-
-
-
Adana, Турция (Туркие), 01060
- Adana Şehir Eğitim ve Araştırma Hastanesi
-
Adapazarı/Turkiye, Турция (Туркие), 54100
- Sakarya Egitim ve Arastirma Hastanesi-Nefroloji
-
Afyonkarahisar, Турция (Туркие), 03200
- Afyonkarahisar Sağlık Bilimleri Üniversitesi Sağlık Uygulama Ve Araştırma Merkezi- Nefroloji
-
Ankara, Турция (Туркие), 06800
- Ankara Bilkent Şehir Hastanesi
-
Ankara, Турция (Туркие), 06500
- Gazi Üniversitesi Hastanesi- Nefroloji
-
Gaziantep, Турция (Туркие), 27070
- Gaziantep Üniversitesi Hastanesi- Nefroloji
-
Izmir, Турция (Туркие), 35100
- Ege Üniversitesi Tip Fakultesi Hastanesi - Nefroloji
-
Kartal/İstanbul, Турция (Туркие), 34865
- Sağlık Bilimleri Üniversitesi Kartal Dr Lütfi Kırdar Şehir Hastanesi - Nefroloji
-
Kocaeli, Турция (Туркие), 41380
- Kocaeli Üniversitesi Araştıma ve Uygulama Hastanesi - Nefroloji
-
Yüreğir/ADANA, Турция (Туркие), 01250
- Başkent Üniversitesi Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi
-
-
Melikgazi
-
Kayseri, Melikgazi, Турция (Туркие), 38039
- Erciyes Üniversitesi Hastanesi - Nefroloji
-
-
-
-
-
Chrudim III, Чехия, 53701
- INTENDIA klinika s.r.o.
-
Prague, Чехия, 150 00
- EUC Klinika Praha a.s.
-
Prague, Чехия, 10400
- ENDOTRIAL s.r.o.
-
Prague, Чехия, 140 00
- Medicon a.s.
-
Prague, Чехия, 149 00
- Milan Kvapil s.r.o.
-
Prague, Чехия, 160 00
- Fledip s.r.o.
-
Prague, Чехия, 190 00
- DiaIn s.r.o.
-
Praha Klanovice, Чехия, 190 14
- TreDia s.r.o.
-
-
-
-
-
Gwangju, Южная Корея, 61453
- Chosun University Hospital_Endocrinology
-
Seoul, Южная Корея, 01830
- Nowon Eulji Medical Center, Eulji University_Endocrinology
-
Seoul, Южная Корея, 03181
- Kangbuk Samsung Hospital_Endocrinology
-
Seoul, Южная Корея, 03080
- Seoul National University Hospital_Endocrinology
-
Seoul, Южная Корея, 03722
- Severance Hospital, Yonsei University Health System_Endocrinology
-
Seoul, Южная Корея, 06591
- The Catholic University of Korea, Seoul ST. Mary's Hospital_Endocrinology
-
Seoul, Южная Корея, 02841
- Korea University Anam Hospital_Endocrinology
-
Seoul, Южная Корея, 04763
- Hanyang University Seoul Hospital_Endocrinology
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Южная Корея, 26426
- Wonju Severance Christian Hospital_Endocrinology
-
-
Gyeonggi-do
-
Bucheon-si, Gyeonggi-do, Южная Корея, 14647
- The Catholic University of Korea, Bucheon ST. Mary's Hospital_Endocrinology
-
-
-
-
-
Aichi, Япония, 468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Arakawa-ku, Tokyo, Япония, 116-0012
- Kumanomae Nishimura Naika Clinic_Internal Medicine
-
Chiba-shi, Chiba, Япония, 260-0804
- Akaicho Clinic_Internal medicine
-
Chikushino-shi, Fukuoka, Япония, 818-0024
- Ito Naika Clinic_Internal Medicine and Diabetology
-
Gifu, Япония, 501-1194
- Gifu University Hospital_Diabetes and Endocrinology
-
Ibaraki, Япония, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Kamakura-shi, Kanagawa, Япония, 247 0072
- Shonan Kamakura General Hospital_Diabetes and Endocrinology
-
Koriyama-shi, Fukushima, Япония, 963-8851
- Seino Internal Medicine Clinic_Internal medicine
-
Minato-ku, Tokyo, Япония, 105-8471
- The Jikei University Hospital_Diabetes, Metabolism, Endocrinology
-
Mito-shi, Ibaraki, Япония, 311-4153
- Minami Akatsuka Clinic_internal medicine
-
Sendai, Miyagi, Япония, 981-8563
- Tohoku Rosai Hospital_Diabetes, Endocrinology and Hypertension
-
Tamana-shi, Kumamoto, Япония, 865-0016
- Higashi Diabetes and Cardiovascular Clinic_Diabetes internal medicine, Cardiology
-
Tokyo, Япония, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Япония, 104-0031
- Fukuwa Clinic_Internal Medicine
-
Tsu-shi, Mie, Япония, 514-1101
- Mie Chuo Medical Center_Department of Diabetes and Endocrinology
-
Wakayama, Япония, 640-8558
- Japanese Red Cross Wakayama Medical Center_Diabetology and Endocrinology
-
-
Japan
-
Oita-shi, Oita,, Japan, Япония, 870 0039
- Abe Diabetes Clinic_Internal Medicine
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Male or female (sex assigned at birth).
- Age 18 years or above at the time of signing the informed consent.
- Diagnosed with type 2 diabetes (T2D) above or equal to 180 days before screening.
- On stable once-daily dose of basal insulin (minimum of 0.25 Unit per kilogram per day or 20 Unit per day) at the investigator's discretion alone or in combination with metformin, sodium-glucose cotransporter 2 inhibitors (SGLT2i) or both (at stable effective or maximum tolerated dose as judged by the investigator) prior to screening. Basal insulin dose is considered stable when all doses during this period are within the range defined by plus minus 20%.
- History of chronic kidney disease based on medical records or as judged by the investigator.
- Treatment with maximum labelled or tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated, in the opinion of the investigator. Treatment dose must be stable for at least 30 days prior to screening.
Exclusion Criteria:
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes or short-term insulin treatment for a maximum of 14 consecutive days is allowed.
- Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
- Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-vascular endothelial growth factor within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for nondilated examination.
- Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening.
- Chronic heart failure classified as being in New York Heart Association Class IV at screening.
- Planned coronary, carotid or peripheral artery revascularisation.
- Lupus nephritis or antineutrophil cytoplasmic (ANCA)-associated vasculitis.
- Any primary or secondary kidney disease requiring immunosuppressive therapy prior to screening.
- Chronic or intermittent haemodialysis or peritoneal dialysis before screening.
- Combination use of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) within 30 days prior to screening.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Плацебо Компаратор: Placebo
Participants will receive placebo matched to zenagamtide subcutaneously. |
Placebo matched to zenagamtide will be administered subcutaneously once weekly. |
|
Экспериментальный: Zenagamtide
Participants will receive zenagamtide subcutaneously. |
Zenagamtide will be administered subcutaneously once weekly. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in glycated haemoglobin (HbA1c)
Временное ограничение: From baseline (week 0) to week 52
|
Measured in percentage (%)-points |
From baseline (week 0) to week 52
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Relative change in body weight
Временное ограничение: From baseline (week 0) to week 52
|
Measured in percentage (%) |
From baseline (week 0) to week 52
|
|
Change in waist circumference
Временное ограничение: From baseline (week 0) to week 52
|
Measured in centimeter (cm) |
From baseline (week 0) to week 52
|
|
Change in triglycerides
Временное ограничение: From baseline (week 0) to week 52
|
Measured as ratio to baseline |
From baseline (week 0) to week 52
|
|
Change in Non-high-density lipoprotein (Non-HDL) cholesterol
Временное ограничение: From baseline (week 0) to week 52
|
Measured as ratio to baseline |
From baseline (week 0) to week 52
|
|
Change in high-sensitivity C-reactive protein (hsCRP)
Временное ограничение: From baseline (week 0) to week 52
|
Measured as ratio to baseline |
From baseline (week 0) to week 52
|
|
Change in systolic blood pressure
Временное ограничение: From baseline (week 0) to week 52
|
Measured in millimeters of mercury (mmHg) |
From baseline (week 0) to week 52
|
|
Change in 7-point self-measured plasma glucose (SMPG) profiles: Mean postprandial increment (over all meals)
Временное ограничение: From baseline (week 0) to week 52
|
Measured in millimole per litre (mmol/L) |
From baseline (week 0) to week 52
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Заболевания эндокринной системы
- Патологические процессы
- Мужские мочеполовые заболевания
- Заболевания почек
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Хроническое заболевание
- Атрибуты болезни
- Метаболические заболевания
- Нарушения метаболизма глюкозы
- Сахарный диабет
- Почечная недостаточность
- Патологические состояния, признаки и симптомы
- Пищевые и метаболические заболевания
- Сахарный диабет, тип 2
- Почечная недостаточность, хроническая
Другие идентификационные номера исследования
- NN9489-8034
- U1111-1335-3313 (Другой идентификатор: World Health Organization (WHO))
- 2026-525471-13 (Другой идентификатор: European Medical Agency (EMA))
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .